Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sutro Biopharma's share price for the quarter that ended in Mar. 2024 was $5.65. Sutro Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 62.5 Mil. Therefore, Sutro Biopharma's market cap for the quarter that ended in Mar. 2024 was $352.9 Mil.
Sutro Biopharma's quarterly market cap
increased
from Sep. 2023 ($211.3 Mil) to Dec. 2023 ($261.7 Mil) and
increased
from Dec. 2023 ($261.7 Mil) to Mar. 2024 ($352.9 Mil).
Sutro Biopharma's annual market cap
declined
from Dec. 2021 ($689.3 Mil) to Dec. 2022 ($464.6 Mil) and
declined
from Dec. 2022 ($464.6 Mil) to Dec. 2023 ($261.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sutro Biopharma's Enterprise Value for Today is $56.8 Mil.
Sutro Biopharma Market Cap Historical Data
The historical data trend for Sutro Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sutro Biopharma's Market Cap
For the Biotechnology subindustry, Sutro Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Market Cap falls into.
Sutro Biopharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sutro Biopharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (NAS:STRO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sutro Biopharma Market Cap Related Terms
Thank you for viewing the detailed overview of Sutro Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sutro Biopharma (Sutro Biopharma) Business Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STRO has been successfully added to your 